Kyverna Therapeutics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor (CAR) T-cell therapies targeting CD19 for the treatment of B cell-driven autoimmune diseases. The company's lead product candidate, KYV-101, is an autologous fully human anti-CD19 CAR T-cell therapy in Phase 2 clinical trials for stiff person syndrome (SPS; KYSA-8 registrational trial), Phase 3 expansion for myasthenia gravis (MG; KYSA-6), and Phase 1/2 for lupus nephritis (LN; KYSA-1 and KYSA-3), with additional studies in multiple sclerosis (MS) and systemic sclerosis (SSc); KYV-102 is an autologous CD19 CAR T-cell candidate incorporating whole blood rapid manufacturing to eliminate apheresis and shorten turnaround time; and KYV-201 is an allogeneic CD19 CAR T-cell therapy, all leveraging a proprietary platform licensed from Intellia Therapeutics for deep B cell depletion and immune system reset aimed at long-term remission. Kyverna operates globally with clinical trials conducted in the United States and Europe, targeting patients with refractory autoimmune conditions including neuroimmunology indications such as SPS and MG. Founded in 2018 and headquartered in Emeryville, California, the company, formerly BAIT Therapeutics, Inc., completed its initial public offering in February 2024. Recent developments include the November 2025 closing of a non-dilutive loan facility with Oxford Finance for up to $150 million (initial $25 million drawn) to support late-stage SPS and generalized MG (gMG) programs and pre-launch activities; expansion of the KYSA-6 MG trial to Phase 3 following positive FDA end-of-Phase 2 meeting, with enrollment starting by year-end 2025; advancement of KYV-102 toward improved manufacturing scalability; and topline registrational SPS data expected in early 2026, amid a prior 2023 Series B extension to $145 million with investors including Bain Capital Life Sciences and GordonMD Global Investments.
Company News
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Kyverna Therapeutics Sinks 13%: Here's Why
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Average Price Target from Analysts